Alpha Cognition Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACOGF research report →
Companywww.alphacognition.com
Alpha Cognition Inc. , a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS.
- CEO
- Michael E. McFadden
- IPO
- 2021
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $35.66M
- P/E
- -39.22
- P/S
- 0.00
- P/B
- -114.63
- EV/EBITDA
- -3.66
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 456.59%
- ROIC
- -926.43%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-13,772,567 · -13.68%
- EPS
- $-0.15 · 16.67%
- Op Income
- $-9,705,601
- FCF YoY
- 5.60%
Performance & Tape
- 52W High
- $5.72
- 52W Low
- $5.72
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.29
- Avg Volume
- 0
Get TickerSpark's AI analysis on ACOGF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ACOGF Coverage
We haven't published any research on ACOGF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACOGF Report →